Proceedings: Prediction of response of disseminated breast cancer to andrenalectomy and oophorectomy using computer aided evaluation of clinical presentation. by Leaper, D. J. & Horrocks, J. C.
ABSTRACTS OF PROFFERED PAPERS 177
Serum oestradiol 17,B was measured
throughout the menstrual cycle in 40 normal
women, in 17 with fibroadenosis, in 12 with
cystic disease and in 10 with cancer of the
breast, by radioimmunoassay (Cameron and
Jones, Steroids, 1972, 20, 737).
Results showed that (1) 36 of the 40
normal premenopausal women exhibited a
constant pattern, but concentrations varied
with age; (2) oestradiol was low during the
follicular phase of the normal cycle (35 3 +
4.4 pg/ml), rose to sharp pre-ovulation peak
(192-9 ± 12-7 pg/ml) and plateaued during
the luteal phase (67.3 ± 1P5 pg/ml); (3)
patients with fibroadenosis showed a con-
centration pattern not significantly different
from normal; (4) in patients with cystic
disease, concentrations were significantly
higher during the luteal phase; (5) patients
with breast cancer considered as a group
showed no consistent divergence from normal
pattern.
OESTROGEN AND ANDROGEN
RECEPTORS IN HUMAN BREAST
CANCER. E. ENGELSMAN, C. B. KORSTEN,
J. P. PERSIJN and F. J. CLETON.
Netherlands Cancer Institute, Amsterdam.
Oestrogen and androgen receptors were
determined in human breast cancer tissue
samples.
Oestrogen receptors were found in 41% of
157 primary cancers and in 46% of 84
metastatic cancers. Androgen receptors were
present in 18% of43 primary tumours and in
22% of 36 secondary lesions.
A strong correlation was found between
the presence of oestrogen receptors in meta-
static tumour tissue and the response to
endocrine therapy: 31 objective remissions
in 39 receptor positive cases and only 4
objective remissions in 45 receptor negative
cases. For androgen receptors no such
correlation was detected in a small number
of evaluable patients.
In 12 patients the presence or absence of
oestrogen receptors did not correlate with the
objective response to endocrine therapy.
Some cases had to be recorded as a failure,
when clinical improvement was present but
without measurable tumour regression. The
receptor content need not be the same in
different metastatic deposits in one patient;
this might explain some discrepancies.
OESTROGEN RECEPTORS IN
HUMAN BREAST CANCER. G.
LECLERCQ, J. C. HEUSON and W. H MATT-
HEIEM. Institut Jules Bordet, Brussels,
Belgium.
Tumour tissue samples from 166 primary
and 136 metastatic breast cancers were
analysed for oestrogen receptors. Cytosol
fractions were incubated with increasing
amounts of 3H-oestradiol-17/3 (LeClercq et al.
Eur. J. Cancer, 1973, 9, 665). Unbound
radioactivity was removed by charcoal-
dextran. Receptors were detected in 72% of
the primary and 54% of the metastatic
tumours. In 86% ofthe " positive " cytosols,
the dissociation constant of the binding
reaction varied between0 5 and20 x 10-10M;
in the remaining 14% the range was from
201 to 132 x 10-10M. At the time of
mastectomy primary tumours were examined
together with the corresponding invaded
axillary lymph nodes. A statistically signi-
ficant correlation was observed between the
amounts of receptors at both sites. In
tumours the concentration of binding sites
varied from zero to 1480 femtomol/mg
protein. The distribution of the cytosols in
regard to this parameter was continuous and
inversely related to it. It is suggested that
the " positive " and " negative " cytosols
may not be qualitatively different, the latter
simply containing receptors in amounts
undetectable by the current methods. Re-
ceptors were never found in various oestrogen
non-target tissues or in sera.
PREDICTION OF RESPONSE OF
DISSEMINATED BREAST CANCER
TO ADRENALECTOMY AND OOPHO-
RECTOMY USING COMPUTER
AIDED EVALUATION OF CLINICAL
PRESENTATION. D. J. LEAPER and
J. C. HORROCKS. Leeds General Infirmary.
Difficulties in predicting response to
hormonal ablation are well known; criteria
employed to make such a distinction vary
from " clinical impression" through dis-
criminant function to more recently reported
assessments (e.g. oestrogen receptors). These
methods however are to some degree fallible,
time-consuming and difficult to perform.
An attempt to predict response to endo-
crine ablation in 100 patients using a com-
puter aided analysis of some 18 clinical signs
and symptoms has been made. Using a178 B.A.C.R. 15TH ANNUAL GENERAL MEETING
simple Bayesian form of analysis, 69%
accuracy overall was achieved in predicting
survival time (with 80% accuracy in those
patients who survived over 2 months) and
accuracy in predicting an objective response
was 82%, and 72% for a subjective response.
These results suggest that: (i) it is possible
in most patients to predict response using
simple clinical parameters and analysis; (ii)
this can be done in routine practice quickly
and easily; and (iii) such a system-if
implemented widely-might be of significant
benefit to individual women suffering from
breast cancer.
p-FLUOROPHENYLALANINE (pFPhe)
AND MITOSIS: INHIBITION AND
RECOVERY OF DIVISION IN HELA
CELLS. D. N. WHEATLEY AND J. Y.
HENDERSON. Department of Pathology,
University of Aberdeen.
pFPhe inhibits the entry of HeLa cells
into division; this effect is known to require
incorporation ofthe amino-acid analogue into
protein (Wheatley and Henderson, Nature,
Lond., 1974, 247, 281). Analysis of the
proteins containing pFPhe made by HeLa
cells on polyacrylamide disc gel electro-
phoresis systems showed excellent agreement
with the Phe proteins. The turnover of
pFPhe proteins also compared closely with
that of the Phe proteins both at 37°C and
400C.
When pFPhe is removed from the culture
medium, cells recover their normal G2 -÷ M
progression in a cycle related manner after a
delay period which depends on both the
concentration and length ofpFPhe exposure.
After careful analysis of conditions per-
mitting recovery, it would appear that a
highly labile protein or group of proteins is
involved which can only suppress mitosis
when pFPhe is maintained at " physio-
logical" levels. At slightly elevated tem-
perature the inhibitory action is accentuated.
A COMPARISON OF CHEMICAL
AND MICROBIOLOGICAL METHODS
FOR ESTIMATING ALKYLATING
AGENT CONCENTRATION. S. M.
ToOGOOD, P. WORKMAN, C. R. BALL and
R. C. GARNER. Department of Cancer
Research, University of Leeds.
Three methods of estimating alkylating
agent concentration have been compared,
initially using aniline mustard as a model
compound: (i) inactivation of E. coli B; (ii)
reaction with 4-p-nitrobenzyl pyridine
(Epstein et al., Anal. Chem., 1955, 27, 1435)
and (iii) formation ofa 35S-thiazan derivative
(Connors, T. A. et al., Biochem. Pharmac.,
1972, 21, 1309).
Quantitation ofthelatterin areproducible
manner has proved difficult and sensitivity is
not as great as expected. Greatest biological
sensitivity amongst DNA repair deficient
strains of E. coli B was shown by uvrA
exrA and uvrA recA mutants. Surprisingly,
a triple mutant polAuvrAexrA was less
sensitive to both aniline and nitrogen
mustards, the reverse being true for methyl
methane sulphonate.
The microbiological method is more
sensitive than either chemical method, parti-
cularly for the more reactive drugs such as
p-hydroxyaniline mustard and nitrogen mus-
tard, and more readily applied in some
instances. The method has enabled drug
adsorption to albumin to be studied. Identi-
fication and estimation of alkylating agents
and their metabolites in biological fluids
should be made possible using this technique.
PREDICTION OF RESPONSE TO
ANTIHORMONE TREATMENT US-
ING AN IN VITRO TEST FOR DE-
PENDENCE OF HORMONES. H.
SALIH, I. DE SOUZA, H. FLAX, K. NEWTON
and J. R. HOBBS. Tumour Biology Group,
Westminster Hospital Medical School.
In vitro hormone dependence has been
defined by detecting enhanced pentose shunt
activity in 24 h cultures of freshly biopsied
human breast cancers after known hormones
have been added to the culture medium.
Four hormones (oestrogen, androgen, pro-
lactin, growth hormone) have been implicated
in half of the 300 breast cancers, and these
could not be assessed adequately by the
previous methods ofstudyingurinarypatterns
ofandrogen excretion or measuring binding to
receptors in homogenates. The clinical
response of 40 patients to antihormonal
treatments revealed: (1) 9/9 oestrogen depen-
dent tumours responding to antioestrogens;
(2) 6/7 androgen dependent tumours respond-
ing to antiandrogenic measures; (3) 5/6
prolactin - growth hormone dependent
tumours responding to satisfactory hypo-
physectomy; (4) 3/3 prolactin dependent